BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37013774)

  • 41. Methyltransferase-like 3 promotes cervical cancer metastasis by enhancing cathepsin L mRNA stability in an N6-methyladenosine-dependent manner.
    Liu P; Ju M; Zheng X; Jiang Y; Yu X; Pan B; Luo R; Jia W; Zheng M
    Cancer Sci; 2023 Mar; 114(3):837-854. PubMed ID: 36382580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Integrative proteomics and m6A microarray analyses of the signatures induced by METTL3 reveals prognostically significant in gastric cancer by affecting cellular metabolism.
    Peng G; Chen S; Zheng N; Tang Y; Su X; Wang J; Dong R; Wu D; Hu M; Zhao Y; Liu M; Wu H
    Front Oncol; 2022; 12():996329. PubMed ID: 36465351
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alternative splicing of METTL3 explains apparently METTL3-independent m6A modifications in mRNA.
    Poh HX; Mirza AH; Pickering BF; Jaffrey SR
    PLoS Biol; 2022 Jul; 20(7):e3001683. PubMed ID: 35853000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non-Small Cell Lung Cancer Prognosis.
    Zhao Z; Cai Q; Zhang P; He B; Peng X; Tu G; Peng W; Wang L; Yu F; Wang X
    Front Mol Biosci; 2021; 8():657087. PubMed ID: 34179079
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer.
    Pan YJ; Huo FC; Kang MJ; Liu BW; Wu MD; Pei DS
    Clin Transl Med; 2022 Nov; 12(11):e1113. PubMed ID: 36394206
    [TBL] [Abstract][Full Text] [Related]  

  • 48. m6A-related bioinformatics analysis and functional characterization reveals that METTL3-mediated NPC1L1 mRNA hypermethylation facilitates progression of atherosclerosis via inactivation of the MAPK pathway.
    Zhang G; Li X; Huang X
    Inflamm Res; 2023 Mar; 72(3):429-442. PubMed ID: 36583755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m6A Methyltransferase METTL3.
    Liao L; He Y; Li SJ; Zhang GG; Yu W; Yang J; Huang ZJ; Zheng CC; He QY; Li Y; Li B
    Cancer Res; 2022 Jul; 82(13):2444-2457. PubMed ID: 35507004
    [TBL] [Abstract][Full Text] [Related]  

  • 50. METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5.
    Zhou D; Tang W; Xu Y; Xu Y; Xu B; Fu S; Wang Y; Chen F; Chen Y; Han Y; Wang G
    Mol Oncol; 2021 Aug; 15(8):2172-2184. PubMed ID: 33411363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
    Liu X; Ma C; Liu H; Sun Z; Luo J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function.
    Du Y; Hou G; Zhang H; Dou J; He J; Guo Y; Li L; Chen R; Wang Y; Deng R; Huang J; Jiang B; Xu M; Cheng J; Chen GQ; Zhao X; Yu J
    Nucleic Acids Res; 2018 Jun; 46(10):5195-5208. PubMed ID: 29506078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. m6A methyltransferase METTL3 inhibits endometriosis by regulating alternative splicing of MIR17HG.
    Li Q; Yang L; Zhang F; Liu J; Jiang M; Chen Y; Ren C
    Reproduction; 2023 Feb; 165(2):197-208. PubMed ID: 36445237
    [TBL] [Abstract][Full Text] [Related]  

  • 54. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
    Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
    [TBL] [Abstract][Full Text] [Related]  

  • 55. METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis.
    Pan J; Liu F; Xiao X; Xu R; Dai L; Zhu M; Xu H; Xu Y; Zhao A; Zhou W; Dang Y; Ji G
    J Exp Clin Cancer Res; 2022 Jan; 41(1):19. PubMed ID: 35012593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The N
    Dorn LE; Lasman L; Chen J; Xu X; Hund TJ; Medvedovic M; Hanna JH; van Berlo JH; Accornero F
    Circulation; 2019 Jan; 139(4):533-545. PubMed ID: 30586742
    [TBL] [Abstract][Full Text] [Related]  

  • 57. METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism.
    Xie W; Ma LL; Xu YQ; Wang BH; Li SM
    Biochem Biophys Res Commun; 2019 Oct; 518(1):120-126. PubMed ID: 31405565
    [TBL] [Abstract][Full Text] [Related]  

  • 58. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma.
    Shen S; Yan J; Zhang Y; Dong Z; Xing J; He Y
    Ann Transl Med; 2021 Jan; 9(1):59. PubMed ID: 33553352
    [TBL] [Abstract][Full Text] [Related]  

  • 59. METTL3-Mediated N6-Methyladenosine Methylation Modifies Foxp3 mRNA Levels and Affects the Treg Cells Proportion in Peripheral Blood of Patients with Asthma.
    Fan L; Wu J; Wang H; Chen Q; He X; Wang Q; Yang Z
    Ann Clin Lab Sci; 2022 Nov; 52(6):884-894. PubMed ID: 36564065
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma.
    Qi LW; Jia JH; Jiang CH; Hu JM
    Front Genet; 2020; 11():614566. PubMed ID: 33519919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.